FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to immunology. Disclosed are chimeric antigenic receptors (CAR), which specifically bind to BCMA (B cell maturing antigen). Also disclosed is a polynucleotide, an expression vector and a T cell. What is also described is a method for engineering an immune cell, methods of treating, a pharmaceutical composition, a method for suppressing growth and progression of a tumour, a method of suppressing metastasis of malignant cells, a method of inducing tumour regress.
EFFECT: present invention can find further application in therapy of a condition associated with malignant cells expressing BCMA (for example, cancer).
49 cl, 2 dwg, 34 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC ANTIBODIES AND THEIR APPLICATION | 2016 |
|
RU2722381C2 |
| CHIMERIC ANTIGENE RECEPTOR | 2019 |
|
RU2810092C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR BCMA AND THEIR USE | 2019 |
|
RU2785658C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN | 2013 |
|
RU2650805C2 |
| MAT-DIRECTED CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING THE ENGINEERED IMMUNE CELLS | 2016 |
|
RU2732925C2 |
| ANTI-TRBC1 ANTIGEN-BINDING DOMAIN | 2018 |
|
RU2791327C2 |
| MOLECULES THAT BIND BCMA AND USE OF SUCH MOLECULES | 2019 |
|
RU2812322C2 |
| ANTIBODIES TO CHIMERIC ANTIGEN RECEPTORS DERIVED FROM 4G7 | 2020 |
|
RU2826051C2 |
| BCMA HEAVY CHAIN ANTIBODIES | 2018 |
|
RU2816994C2 |
